CytoDyn (CYDY) Payables (2011 - 2026)

CytoDyn's Payables history runs 16 years deep, the most recent figure standing at $22.9 million for Q1 2026.

• Quarterly Payables fell 0.74% year-over-year to $22.9 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $22.9 million (down 0.74% YoY) and the FY2025 annual result came in at $23.0 million, down 36.84% from the prior year.
• Payables was $22.9 million for Q1 2026 at CytoDyn, down from $23.3 million in the prior quarter.
• Across five years, Payables topped out at $73.4 million in Q3 2022 and bottomed at $21.3 million in Q3 2024.
• A 5-year average of $48.7 million and a median of $66.0 million in 2022 frame the typical range for Payables.
• Annual changes were most pronounced in 2022 — Payables increased 17.91% — and 2024, when it slumped 70.72%.
• CytoDyn's Payables stood at $72.5 million in 2022, then decreased by 5.63% to $68.4 million in 2023, then tumbled by 68.17% to $21.8 million in 2024, then gained by 6.8% to $23.3 million in 2025, then decreased by 1.73% to $22.9 million in 2026.
• Business Quant data shows CYDY's Payables at $22.9 million in Q1 2026, $23.3 million in Q4 2025, and $22.8 million in Q3 2025.